Kedrion CEO Assumes Board Helm of PPTA
The Plasma Protein Therapeutics Association (PPTA) is proud to announce that the Global Board of Directors elected Paolo Marcucci, as Chairman at its meeting in Brussels, Belgium today.
In 2003, Paolo Marcucci became President of Kedrion, a biopharmaceutical company specializing in the development, production and distribution of plasma-derived products. In 2006 he became Chief Executive Officer (CEO) and in 2011 he became CEO of Kedrion Biopharma, a U.S. subsidiary of the Kedrion Group. He has served on the PPTA Global Board of Directors since 2008. "It will be a great honor and privilege to serve as the new chairman of PPTA. I look forward to continuing the work of my predecessor to improve patient access to critically needed safe plasma protein therapies," Mr. Marcucci said.
Mr. Marcucci has coordinated and directed research projects related to plasma proteins, coagulation factors and vaccines that have resulted in new pharmaceutical products and purification methods that contribute to product efficacy and safety. At Kedrion's helm he oversees company operations in Italy, Hungary and the United States.
"It will be a pleasure to work with Paolo who will bring a new dimension to this role. It is also nice that he is going to lead this Board, knowing that his father, Guelfo Marcucci was one of the founders of PPTA," said Jan M. Bult, PPTA President and CEO.
Mr. Marcucci succeeds Paul Perreault, CSL, who served as chair since 2012 and will remain on the Board. "PPTA thanks him for his leadership and wishes him a lot of success in his new role as CEO of CSL," Bult added.
PPTA's Global Board is committed to ensuring patient access to therapies, the safety and quality of plasma collection and the manufacturing of plasma protein therapies and sustained innovation that helps save and improve lives throughout the world.
- Created on .